Lamotrigine promotes reentrant ventricular tachycardia in murine hearts
Epilepsia · 2025
DOI: 10.1111/epi.18295 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, 2025. Verfasst von Patrícia Dias und 5 weiteren Autor:innen. Beteiligte Einrichtung: Frick Center for Heart Failure and Arrhythmia, Dorothy M. Davis Heart and Lung Research Institute, College of Medicine, Ohio State University Wexner …. Hauptthemen laut MEDLINE: Lamotrigine, Tachycardia, Ventricular, Anti-Arrhythmia Agents, Anticonvulsants. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NINDS NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Objective
In 2021, the US Food and Drug Administration issued a safety warning concerning lamotrigine use in patients with underlying cardiac disorders. This warning was based on in vitro data that predicted class Ib antiarrhythmic activity for lamotrigine. Therefore, we investigated the proarrhythmic potential of lamotrigine in the murine heart and compared its effect with flecainide.
Methods
Murine hearts were perfused with clinically relevant concentrations of lamotrigine 3.8 μg/mL (15 μmol·L −1 ) or flecainide .4 μg/mL (1 μmol·L −1 ).
Results
Ex vivo electrocardiography revealed a high prevalence of ventricular tachycardia (VT) in lamotrigine‐perfused hearts (7/9 hearts), whereas only two hearts exposed to flecainide evidenced VT. Optical voltage mapping showed that lamotrigine preferentially decreased ventricular conduction velocity (CV) in the longitudinal direction at all pacing frequencies tested (−22% ± 8.6%, −30% ± 15.4%, and −33% ± 13.3% for pacing frequency of 200‐ms, 180‐ms, and 150‐ms cycle length, respectively, p ≤ .05) compared to the transverse direction, which only slowed CV at the fastest pacing frequency (−15% ± 16% for pacing frequency of 150‐ms cycle length, p ≤ .01). Notably, the preferential CV slowing in the longitudinal direction altered the anisotropic ratio, giving rise to a functional substrate for reentrant VT. In contrast, flecainide slowed CV uniformly in both longitudinal and transverse directions (−30% ± 8.5% vs. −27% ± 5.3%, −32% ± 9.4% vs. −29% ± 6.9%, and − 29% ± 8.3% vs. −27% ± 10% for pacing frequency of 200‐ms, 180‐ms, and 150‐ms cycle length, respectively, p ≤ .05). Significance Our findings provide mechanistic insight into the proarrhythmic impact of lamotrigine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Frick Center for Heart Failure and Arrhythmia, Dorothy M. Davis Heart and Lung Research Institute, College of Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
- Division of Pharmaceutics and Pharmacology, College of Pharmacy, Ohio State University, Columbus, Ohio, USA.
- Department of Biomedical Engineering, College of Engineering, Ohio State University, Columbus, Ohio, USA.
ORCID-Profile: Heather Struckman, Przemysław B Radwański
Förderung
- NHLBI NIH HHS
- NINDS NIH HHS
- National Heart, Lung, and Blood Institute
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Dias, P., Meng, X., Selimi, Z., Struckman, H., Veeraraghavan, R., & Radwański, P. B. (2025). Lamotrigine promotes reentrant ventricular tachycardia in murine hearts. Epilepsia. https://doi.org/10.1111/epi.18295
Vancouver
Dias P, Meng X, Selimi Z, Struckman H, Veeraraghavan R, Radwański PB. Lamotrigine promotes reentrant ventricular tachycardia in murine hearts. Epilepsia. 2025. doi:10.1111/epi.18295
BibTeX
@article{Dias2025,
author = {Dias, Patrícia and Meng, Xiaolei and Selimi, Zoja and Struckman, Heather and Veeraraghavan, Rengasayee and Radwański, Przemysław B},
title = {Lamotrigine promotes reentrant ventricular tachycardia in murine hearts},
journal = {Epilepsia},
year = {2025},
doi = {10.1111/epi.18295}
}
EUVIMED